Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 3,694,626
- Share change
- +24,561
- Total reported value
- $148,579,853
- Price per share
- $40.23
- Number of holders
- 51
- Value change
- -$338,275
- Number of buys
- 28
- Number of sells
- 19
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC |
13F
13D/G
|
Company |
8.9%
from 13D/G
|
5,888,888
|
$298,213,288 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13D/G
13F
|
T. Rowe Price Associates, Inc. · Company |
7.7%
|
5,461,988
|
$276,595,072 | +$90,918,550 | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.7%
|
4,825,519
|
$244,364,280 | — | 31 Dec 2025 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
5.6%
|
4,059,695
|
$205,582,955 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
13D/G
|
Company · The Vanguard Group |
5%
from 13D/G
|
3,570,401
|
$180,805,107 | — | 31 Dec 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
5.5%
|
3,921,362
|
$176,892,640 | $0 | 04 Mar 2026 | |
| Kynam Capital Management, LP |
13F
13D/G
|
Company |
5.4%
from 13D/G
|
3,433,051
|
$173,849,703 | — | 31 Dec 2025 | |
| Eversept Partners, LP |
13F
|
Company |
4.2%
|
3,072,304
|
$155,581,475 | — | 31 Dec 2025 | |
| FMR LLC |
13F
13D/G
|
Company |
4.1%
from 13D/G
|
2,885,853
|
$146,139,597 | — | 31 Dec 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
3.9%
|
2,793,987
|
$141,487,502 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.7%
|
2,676,600
|
$135,543,024 | — | 31 Dec 2025 | |
| Sofinnova Venture Partners X, L.P. |
13D/G
3/4/5
|
Dr. Maha Katabi ("Katabi") · 10%+ Owner |
4%
|
2,847,837
|
$128,465,927 | $0 | 10 Dec 2025 | |
| Patrick G. Enright |
3/4/5
|
Director |
—
mixed-class rows
|
3,616,475
mixed-class rows
|
$102,609,021 | +$5,527,296 | 11 Dec 2025 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
2.5%
|
1,800,000
|
$91,152,000 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
13D/G
|
Company |
1.7%
from 13D/G
|
1,738,385
|
$88,031,816 | — | 31 Dec 2025 | |
| Bellevue Group AG |
13F
|
Company |
2.3%
|
1,698,152
|
$85,994,417 | — | 31 Dec 2025 | |
| Commodore Capital LP |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,400,000
|
$79,200,000 | — | 10 Jan 2024 | |
| James E. Flynn |
13D/G
|
Deerfield Mgmt, L.P. |
5.2%
|
3,348,117
|
$75,299,151 | $0 | 06 Jun 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
1,444,925
|
$73,185,024 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.9%
|
1,392,421
|
$70,512,199 | — | 31 Dec 2025 | |
| Holocene Advisors, LP |
13F
|
Company |
1.8%
|
1,307,393
|
$66,206,382 | — | 31 Dec 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
1.7%
|
1,218,657
|
$61,712,790 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.5%
|
1,120,780
|
$56,756,299 | — | 31 Dec 2025 | |
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| Abingworth LLP |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,970,156
mixed-class rows
|
$53,284,158 | — | 13 May 2021 | |
| Carlyle Group Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,960,231
|
$53,284,158 | — | 17 Aug 2022 | |
| Woodline Partners LP |
13F
|
Company |
1.4%
|
1,000,279
|
$50,654,129 | — | 31 Dec 2025 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.2%
|
869,676
|
$44,040,393 | — | 31 Dec 2025 | |
| Tri Locum Partners LP |
13F
|
Company |
1.1%
|
805,689
|
$40,800,091 | — | 31 Dec 2025 | |
| BRAIDWELL LP |
13F
|
Company |
1.1%
|
784,742
|
$39,739,335 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
1.1%
|
777,488
|
$39,371,992 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
1%
|
732,699
|
$37,103,945 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.96%
|
694,319
|
$35,160,313 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
0.9%
|
653,796
|
$33,108,229 | — | 31 Dec 2025 | |
| Longitude Capital Partners IV, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| Longitude Prime Partners, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,714,285
|
$30,857,130 | — | 06 Feb 2023 | |
| First Turn Management, LLC |
13F
|
Company |
0.83%
|
601,774
|
$30,473,835 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.79%
|
568,579
|
$28,792,841 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
|
Company |
0.76%
|
550,000
|
$27,852,000 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.72%
|
518,858
|
$26,274,969 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.69%
|
499,665
|
$25,303,052 | — | 31 Dec 2025 | |
| Elmind Capital, LP |
13F
|
Company |
0.67%
|
482,500
|
$24,433,800 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0.66%
|
474,668
|
$24,037,188 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.65%
|
473,219
|
$23,963,810 | — | 31 Dec 2025 | |
| S.c.a. Candriam |
13F
|
Individual |
0.62%
|
449,554
|
$22,766,384 | — | 31 Dec 2025 | |
| Rhenman & Partners Asset Management AB |
13F
|
Company |
0.58%
|
420,000
|
$21,268,800 | — | 31 Dec 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.58%
|
418,963
|
$21,216,287 | — | 31 Dec 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.52%
|
378,055
|
$19,144,705 | — | 31 Dec 2025 | |
| FRONTIER CAPITAL MANAGEMENT CO LLC |
13F
|
Company |
0.51%
|
371,151
|
$18,795,087 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.49%
|
353,500
|
$17,901,240 | — | 31 Dec 2025 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q1 2026
As of 31 Mar 2026,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,694,626 shares.
The largest 10 holders included
Pictet Asset Management Holding SA, DEUTSCHE BANK AG\, Candriam S.C.A., Nuveen, LLC, DIMENSIONAL FUND ADVISORS LP, TimesSquare Capital Management, LLC, UBS Group AG, Bank of New York Mellon Corp, CenterBook Partners LP, and Swiss National Bank.
This page lists
55
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
213
Q1 2026 holders
51
Holder diff
-162
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.